These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 33015652)

  • 1. Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study.
    Wajnberg A; Mansour M; Leven E; Bouvier NM; Patel G; Firpo-Betancourt A; Mendu R; Jhang J; Arinsburg S; Gitman M; Houldsworth J; Sordillo E; Paniz-Mondolfi A; Baine I; Simon V; Aberg J; Krammer F; Reich D; Cordon-Cardo C
    Lancet Microbe; 2020 Nov; 1(7):e283-e289. PubMed ID: 33015652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence of SARS-CoV-2 nasopharyngeal swab PCR positivity in COVID-19 convalescent plasma donors.
    Ikegami S; Benirschke R; Flanagan T; Tanna N; Klein T; Elue R; Debosz P; Mallek J; Wright G; Guariglia P; Kang J; Gniadek TJ
    Transfusion; 2020 Dec; 60(12):2962-2968. PubMed ID: 32840002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples.
    Anand SP; Prévost J; Richard J; Perreault J; Tremblay T; Drouin M; Fournier MJ; Lewin A; Bazin R; Finzi A
    Transfusion; 2021 May; 61(5):1377-1382. PubMed ID: 33604922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.
    Havervall S; Ng H; Jernbom Falk A; Greilert-Norin N; Månberg A; Marking U; Laurén I; Gabrielsson L; Salomonsson AC; Aguilera K; Kihlgren M; Månsson M; Rosell A; Hellström C; Andersson E; Olofsson J; Skoglund L; Yousef J; Pin E; Lord M; Åberg M; Hedhammar M; Tegel H; Dönnes P; Phillipson M; Nilsson P; Klingström J; Mangsbo S; Hober S; Thålin C
    J Intern Med; 2022 Jan; 291(1):72-80. PubMed ID: 34459525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk Factors for Being Seronegative following SARS-CoV-2 Infection in a Large Cohort of Health Care Workers in Denmark.
    Johannesen CK; Rezahosseini O; Gybel-Brask M; Kristensen JH; Hasselbalch RB; Pries-Heje MM; Nielsen PB; Knudsen AD; Fogh K; Norsk JB; Andersen O; Jensen CAJ; Torp-Pedersen C; Rungby J; Ditlev SB; Hageman I; Møgelvang R; Dessau RB; Sørensen E; Harritshøj LH; Folke F; Sten C; Møller MEE; Engsig FN; Ullum H; Jørgensen CS; Ostrowski SR; Bundgaard H; Iversen KK; Fischer TK; Nielsen SD
    Microbiol Spectr; 2021 Oct; 9(2):e0090421. PubMed ID: 34668738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels.
    Harvala H; Robb ML; Watkins N; Ijaz S; Dicks S; Patel M; Supasa P; Wanwisa D; Liu C; Mongkolsapaya J; Bown A; Bailey D; Vipond R; Grayson N; Temperton N; Gupta S; Ploeg RJ; Bolton J; Fyfe A; Gopal R; Simmonds P; Screaton G; Thompson C; Brooks T; Zambon M; Miflin G; Roberts DJ
    Transfus Med; 2021 Jun; 31(3):167-175. PubMed ID: 33333627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies.
    Schuler CF; Gherasim C; O'Shea K; Manthei DM; Chen J; Zettel C; Troost JP; Kennedy AA; Tai AW; Giacherio DA; Valdez R; Baldwin JL; Baker JR
    Microbiol Spectr; 2021 Oct; 9(2):e0008721. PubMed ID: 34468184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum.
    Lu L; Chu AW; Zhang RR; Chan WM; Ip JD; Tsoi HW; Chen LL; Cai JP; Lung DC; Tam AR; Yau YS; Kwan MY; To WK; Tsang OT; Lee LL; Yi H; Ip TC; Poon RW; Siu GK; Mok BW; Cheng VC; Chan KH; Yuen KY; Hung IF; To KK
    EBioMedicine; 2021 Sep; 71():103544. PubMed ID: 34419925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal humoral antibody response to SARS-CoV-2 infection among healthcare workers in a New York City hospital.
    Menon V; Shariff MA; Perez Gutierrez V; Carreño JM; Yu B; Jawed M; Gossai M; Valdez E; Pillai A; Venugopal U; Kasubhai M; Dimitrov V; Krammer F
    BMJ Open; 2021 Oct; 11(10):e051045. PubMed ID: 34702729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent viral RNA shedding after COVID-19 symptom resolution in older convalescent plasma donors.
    Hartman WR; Hess AS; Connor JP
    Transfusion; 2020 Oct; 60(10):2189-2191. PubMed ID: 32533556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody indexes in COVID-19 convalescent plasma donors: Unanswered questions.
    Bonetti TCS; Latini FRM; Invitti AL; Fonseca MCM; Scorza FA; Saldanha MG; Bellucco FT; Bacarov NBS; Soane MM; Girão MJBC
    Clinics (Sao Paulo); 2021; 76():e2818. PubMed ID: 34468538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
    Lu L; Zhang H; Zhan M; Jiang J; Yin H; Dauphars DJ; Li SY; Li Y; He YW
    Sci China Life Sci; 2020 Dec; 63(12):1833-1849. PubMed ID: 33355886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis.
    Yang W; Kandula S; Huynh M; Greene SK; Van Wye G; Li W; Chan HT; McGibbon E; Yeung A; Olson D; Fine A; Shaman J
    Lancet Infect Dis; 2021 Feb; 21(2):203-212. PubMed ID: 33091374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study.
    Trieu MC; Bansal A; Madsen A; Zhou F; Sævik M; Vahokoski J; Brokstad KA; Krammer F; Tøndel C; Mohn KGI; Blomberg B; Langeland N; Cox RJ;
    J Infect Dis; 2021 Feb; 223(4):589-599. PubMed ID: 33247924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects.
    Huynh A; Arnold DM; Smith JW; Moore JC; Zhang A; Chagla Z; Harvey BJ; Stacey HD; Ang JC; Clare R; Ivetic N; Chetty VT; Bowdish DME; Miller MS; Kelton JG; Nazy I
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33923828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-Reactivity of SARS-CoV-2 Nucleocapsid-Binding Antibodies and Its Implication for COVID-19 Serology Tests.
    Rak A; Donina S; Zabrodskaya Y; Rudenko L; Isakova-Sivak I
    Viruses; 2022 Sep; 14(9):. PubMed ID: 36146847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing activity to SARS-CoV-2 in 1.2 to 10.0 month convalescent plasma samples of COVID-19: A transversal surrogate in vitro study performed in Quito-Ecuador.
    Villacrés-Granda B; Paz E; Burbano MJ; Villacrés-Granda I; Armijos D; Aguirre M
    J Med Virol; 2022 Sep; 94(9):4246-4252. PubMed ID: 35585654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.